Larimar Therapeutics, Inc. (LRMR) SEC Filings — 2025
16 SEC filings for Larimar Therapeutics, Inc. (LRMR) in 2025.
Filings
- Larimar Therapeutics, Inc. 8-K Filing — 8-K · Dec 17, 2025
- Larimar Therapeutics, Inc. 8-K Filing — 8-K · Nov 10, 2025
- Larimar's R&D Surge Drives Q3 Loss to $47.7M Amid Nomlabofusp Push — 10-Q · Nov 5, 2025
- Larimar Therapeutics Files 8-K — 8-K · Oct 14, 2025
- Larimar Therapeutics Files 8-K — 8-K · Sep 29, 2025
- Larimar's R&D Surge Drives 53% Net Loss Increase Amid Clinical Trials — 10-Q · Aug 14, 2025
- Larimar Therapeutics Files 8-K with Material Agreement — 8-K · Jul 31, 2025
- Larimar Therapeutics Files 8-K Report — 8-K · Jul 29, 2025
- Larimar Therapeutics Files 8-K — 8-K · Jun 23, 2025
- Larimar Therapeutics Files 8-K on Shareholder Votes — 8-K · May 13, 2025
- Larimar Therapeutics Files 8-K — 8-K · May 5, 2025
- Larimar Therapeutics Files Q1 2025 10-Q — 10-Q · Apr 30, 2025
- Larimar Therapeutics DEF 14A: Executive Compensation Details — DEF 14A · Apr 11, 2025
- Larimar Therapeutics Files 2024 10-K — 10-K · Mar 24, 2025
- Larimar Therapeutics Appoints New CEO, Board Member — 8-K · Jan 27, 2025
- Larimar Therapeutics Files 8-K — 8-K · Jan 10, 2025